Peptide Suppliers in AI Search: The Biggest AI Visibility Problems and How We'd Fix Them

Mark HuntleyBy Mark HuntleyFounder and CEO
18 minutes read

Key Takeaways

  • Phoenix Pharmaceuticals led the set with the most mentions, recommendations and top placements across the benchmark.
  • Biotech Peptides and Core Peptides also showed strong presence, while the rest of the field trailed far behind.
  • Blue Sky Peptide and Peptide Tech had the largest fact-checking issues, including conflicting claims about operating status.
  • The recommended next steps are to verify disputed facts, review owned pages and third-party sources, and build a baseline scorecard for future comparisons.

Companies covered: AminoVault, Peptide Tech, Core Peptides, Peptides Source, Biotech Peptides, Blue Sky Peptide, Phoenix Pharmaceuticals

Answer Capsule

The November 2026 Peptide Suppliers benchmark compares 7 companies across 453 AI answers that met its inclusion rules. Phoenix Pharmaceuticals recorded 178 mentions and 117 recommendations (25.83% of the answers). Being mentioned means appearing in an answer; being recommended means receiving an affirmative endorsement.

We examine each company, establish the current research baseline, and set out a five-step plan for improving the information AI systems can draw on. The work starts with measuring visibility and checking conflicting claims, then moves to company pages, relevant publishers and buyer questions. The cited pages need review before any correction request, and the research does not establish what caused recommendation differences or promise future gains.

Executive industry diagnosis

Questions This Section Answers

  • What does the Peptide Suppliers benchmark show about mentions, recommendations and placement?

Rank

Company

Mentions

Mention rate

Recommendations

Recommendation rate

Top 3

Top 3 rate

#1

#1 rate

1

Phoenix Pharmaceuticals

178

39.29%

117

25.83%

94

20.75%

58

12.80%

2

Biotech Peptides

142

31.35%

91

20.09%

70

15.45%

28

6.18%

3

Core Peptides

152

33.55%

72

15.89%

59

13.02%

17

3.75%

4

AminoVault

33

7.28%

27

5.96%

17

3.75%

5

1.10%

5

Peptides Source

10

2.21%

4

0.88%

3

0.66%

1

0.22%

6

Blue Sky Peptide

36

7.95%

3

0.66%

3

0.66%

0

0.00%

7

Peptide Tech

7

1.55%

0

0.00%

0

0.00%

0

0.00%

The peer set splits into a clear leading group and a long tail. Phoenix Pharmaceuticals, Biotech Peptides and Core Peptides each appear in a large share of answers and also carry substantial recommendation counts, so their presence is not merely incidental name-dropping. The remaining companies appear far less often, and their recommendation counts fall away faster than their mention counts.

The most instructive contrast is between reach and endorsement. Blue Sky Peptide appears more often than AminoVault, yet its mentions included an endorsement only a handful of times, while AminoVault's smaller presence carried a higher share of mentions with a recommendation. Peptide Tech appears without any recorded recommendation at all. These are recorded answer patterns, not customer outcomes, and they point to different starting problems: some companies need more presence, others need clearer affirmative support.

A single visibility number would mislead, so the scorecard should track mentions, recommendations and placement separately, starting where the gap between appearance and endorsement is widest.

What changed since last month

Questions This Section Answers

  • What changed across the usable monthly Peptide Suppliers snapshots?

Company

Nov 2026

Phoenix Pharmaceuticals

117 / 453 (25.83%)

Biotech Peptides

91 / 453 (20.09%)

Core Peptides

72 / 453 (15.89%)

AminoVault

27 / 453 (5.96%)

Peptides Source

4 / 453 (0.88%)

Blue Sky Peptide

3 / 453 (0.66%)

Peptide Tech

0 / 453 (0.00%)

Only months with verified results are shown. Monthly sample coverage is listed in Methodology.

This edition is the first broad baseline, so the monthly figures should be read as a single snapshot rather than a trend line. Earlier editions used a narrower question set, which means their numbers are not comparable with these results and cannot support a claim that any company gained or lost ground.

The useful history here is procedural: the same screening scope now exists, so future editions can be compared against it. Until then, the agency should treat this month as the reference point and avoid drawing movement conclusions from a sample that changed shape.

AI recommendation trend

Observed recommendation rate (%), Nov 2026

  • Phoenix Pharmaceuticalsno change
    Nov 202625.83%
  • Biotech Peptidesno change
    Nov 202620.09%
  • Core Peptidesno change
    Nov 202615.89%
  • AminoVaultno change
    Nov 20265.96%
  • Peptides Sourceno change
    Nov 20260.88%
  • Blue Sky Peptideno change
    Nov 20260.66%
  • Peptide Techno change
    Nov 20260.00%

Separate selected monthly samples. Missing points are unavailable, not zero. Provider/prompt equivalence is unverified; rate movement does not demonstrate causation.

Company-by-company findings

AminoVault

Questions This Section Answers

  • What measured visibility pattern and review priority does AminoVault have in Peptide Suppliers?

AminoVault recorded 33 mentions (7.28%) and 27 recommendations (5.96%) across 453 answers included in the benchmark. Top 3 placements numbered 17; first-place recommendations numbered 5. Framing among its mentions was 27 positive, 6 neutral and 0 negative.

This edition establishes a broader research baseline. Earlier editions used a narrower set of questions, so their figures are not treated as a performance trend.

AI answers contained 0 conflicting claims about AminoVault: 0 critical, 0 high, 0 medium, 0 low. Of these, 0 were rated critical or high priority; the critical claims are included in that total. These ratings help prioritize fact-checking. They do not establish that a company or publisher made an error.

No results are available for this part of the analysis.

Both columns quote AI answers, not verified company facts. Resolve the entity, date and source before deciding whether a correction is warranted; different dates can explain an apparent conflict.

Question observed in the research

Benchmark answers to this question

Company mentions

Company recommendations

What is the best peptide company?

3

2

2

Who makes research peptides in the US?

3

2

2

These are recorded answer observations, not search volume, verified demand, or proof of missing website content.

Selected owned-page review candidate: https://aminovault.com/.

Selected third-party review candidate: https://onetwenty.com/blog/peptide-companies.

AminoVault's presence is modest but unusually endorsement-heavy: most of its mentions also carried a recommendation, and its framing was almost entirely positive. That combination suggests a company that answers treat favorably when it comes up, rather than one that dominates the conversation.

The proposed work is a conditional page and source review: confirm current company facts against primary sources, then decide whether any brief is warranted. No correction should be proposed until that verification is complete.

Peptide Tech

Questions This Section Answers

  • What measured visibility pattern and review priority does Peptide Tech have in Peptide Suppliers?

Peptide Tech recorded 7 mentions (1.55%) and 0 recommendations (0.00%) across 453 answers included in the benchmark. Top 3 placements numbered 0; first-place recommendations numbered 0. Framing among its mentions was 0 positive, 7 neutral and 0 negative.

This edition establishes a broader research baseline. Earlier editions used a narrower set of questions, so their figures are not treated as a performance trend.

AI answers contained 2 conflicting claims about Peptide Tech: 2 critical, 0 high, 0 medium, 0 low. Of these, 2 were rated critical or high priority; the critical claims are included in that total. These ratings help prioritize fact-checking. They do not establish that a company or publisher made an error.

Review topic

Severity

Recorded AI claim A

Recorded AI claim B

is it still in business / storefront availability

critical

active online supplier with working checkout

storefront shut down; not currently selling retail

is it still in business / storefront availability

critical

active online supplier with working checkout

storefront shut down; not currently selling retail

Both columns quote AI answers, not verified company facts. Resolve the entity, date and source before deciding whether a correction is warranted; different dates can explain an apparent conflict.

Question observed in the research

Benchmark answers to this question

Company mentions

Company recommendations

Is Peptide Tech legit?

4

4

0

Which peptide company is made in the USA?

4

1

0

These are recorded answer observations, not search volume, verified demand, or proof of missing website content.

Selected owned-page review candidate: https://peptidetech.co/usa-made-peptides-trusted-supplier-custom-synthesis/.

Selected third-party review candidate: https://disclosedlabs.com/vendors/peptide-tech.

Peptide Tech appears in answers but never with an affirmative recommendation, and all of its recorded framing was neutral. The priority is understanding that absence before setting any visibility target, since a neutral appearance and an endorsement are different outcomes.

The recorded conflicts about whether the business is operating are the more urgent issue. Proposed work is a fact-check against current primary sources, with any correction request held until the company's status is confirmed.

Core Peptides

Questions This Section Answers

  • What measured visibility pattern and review priority does Core Peptides have in Peptide Suppliers?

Core Peptides recorded 152 mentions (33.55%) and 72 recommendations (15.89%) across 453 answers included in the benchmark. Top 3 placements numbered 59; first-place recommendations numbered 17. Framing among its mentions was 79 positive, 69 neutral and 4 negative.

This edition establishes a broader research baseline. Earlier editions used a narrower set of questions, so their figures are not treated as a performance trend.

AI answers contained 5 conflicting claims about Core Peptides: 0 critical, 1 high, 4 medium, 0 low. Of these, 1 was rated critical or high priority; the critical claims are included in that total. These ratings help prioritize fact-checking. They do not establish that a company or publisher made an error.

Review topic

Severity

Recorded AI claim A

Recorded AI claim B

is it still in business / availability

high

actively operating and recommended as dependable vendor

closed as part of gray-market research vendor crackdown

Trustpilot presence / review rating

medium

Trustpilot profile removed; only Knoji reviews (4.0/5)

Strong overall rating on Trustpilot

Both columns quote AI answers, not verified company facts. Resolve the entity, date and source before deciding whether a correction is warranted; different dates can explain an apparent conflict.

Question observed in the research

Benchmark answers to this question

Company mentions

Company recommendations

What are the most popular peptide brands?

4

4

4

What is the best peptide company in the US?

5

3

3

These are recorded answer observations, not search volume, verified demand, or proof of missing website content.

Selected owned-page review candidate: https://corepeptides.com/.

Selected third-party review candidate: https://peptidestack.io/blog/core-peptides-review-2026.

Core Peptides combines strong presence with a solid recommendation share, placing it among the leading group. Its framing is mostly positive with little negative wording, so the opportunity is less about repairing perception than about sustaining a favorable position.

The recorded conflicts concern operating status and review presence, one of them rated high priority. Proposed work is a scoped fact check against current primary sources, followed by a page brief only if the verified facts support one.

Peptides Source

Questions This Section Answers

  • What measured visibility pattern and review priority does Peptides Source have in Peptide Suppliers?

Peptides Source recorded 10 mentions (2.21%) and 4 recommendations (0.88%) across 453 answers included in the benchmark. Top 3 placements numbered 3; first-place recommendations numbered 1. Framing among its mentions was 4 positive, 6 neutral and 0 negative.

This edition establishes a broader research baseline. Earlier editions used a narrower set of questions, so their figures are not treated as a performance trend.

AI answers contained 0 conflicting claims about Peptides Source: 0 critical, 0 high, 0 medium, 0 low. Of these, 0 were rated critical or high priority; the critical claims are included in that total. These ratings help prioritize fact-checking. They do not establish that a company or publisher made an error.

No results are available for this part of the analysis.

Both columns quote AI answers, not verified company facts. Resolve the entity, date and source before deciding whether a correction is warranted; different dates can explain an apparent conflict.

Question observed in the research

Benchmark answers to this question

Company mentions

Company recommendations

Are there alternatives to Swiss Chems?

1

1

1

What is the best company to buy peptides from?

3

1

1

These are recorded answer observations, not search volume, verified demand, or proof of missing website content.

Selected owned-page review candidate: https://peptidessource.com/.

Selected third-party review candidate: https://phoenixpeptide.com/product_category/peptides/.

Peptides Source has limited presence and few recommendations, with framing leaning neutral. At this scale, the figures describe a company on the edge of the conversation rather than one with a clear endorsement problem.

No conflicting claims were recorded, so there is no correction queue to work through. Proposed work is a light page review to confirm current facts, with any content brief deferred until a later edition shows whether the pattern holds.

Biotech Peptides

Questions This Section Answers

  • What measured visibility pattern and review priority does Biotech Peptides have in Peptide Suppliers?

Biotech Peptides recorded 142 mentions (31.35%) and 91 recommendations (20.09%) across 453 answers included in the benchmark. Top 3 placements numbered 70; first-place recommendations numbered 28. Framing among its mentions was 95 positive, 47 neutral and 0 negative.

This edition establishes a broader research baseline. Earlier editions used a narrower set of questions, so their figures are not treated as a performance trend.

AI answers contained 0 conflicting claims about Biotech Peptides: 0 critical, 0 high, 0 medium, 0 low. Of these, 0 were rated critical or high priority; the critical claims are included in that total. These ratings help prioritize fact-checking. They do not establish that a company or publisher made an error.

No results are available for this part of the analysis.

Both columns quote AI answers, not verified company facts. Resolve the entity, date and source before deciding whether a correction is warranted; different dates can explain an apparent conflict.

Question observed in the research

Benchmark answers to this question

Company mentions

Company recommendations

What are the best peptide companies in the US?

4

3

3

What are the best peptide shops?

3

3

3

These are recorded answer observations, not search volume, verified demand, or proof of missing website content.

Selected owned-page review candidate: https://biotechpeptides.com/.

Selected third-party review candidate: https://americanpeptides.us/.

Biotech Peptides sits firmly in the leading group, with high presence, a strong recommendation share and no negative framing recorded. Its answers also carried no conflicting claims, which makes it the least factually contested of the major names.

The proposed work is therefore maintenance rather than repair: a page review to confirm that current company facts match what answers describe, and a scorecard entry that tracks whether its endorsement share holds as the baseline is repeated.

Blue Sky Peptide

Questions This Section Answers

  • What measured visibility pattern and review priority does Blue Sky Peptide have in Peptide Suppliers?

Blue Sky Peptide recorded 36 mentions (7.95%) and 3 recommendations (0.66%) across 453 answers included in the benchmark. Top 3 placements numbered 3; first-place recommendations numbered 0. Framing among its mentions was 6 positive, 21 neutral and 9 negative.

This edition establishes a broader research baseline. Earlier editions used a narrower set of questions, so their figures are not treated as a performance trend.

AI answers contained 24 conflicting claims about Blue Sky Peptide: 15 critical, 0 high, 3 medium, 6 low. Of these, 15 were rated critical or high priority; the critical claims are included in that total. These ratings help prioritize fact-checking. They do not establish that a company or publisher made an error.

Review topic

Severity

Recorded AI claim A

Recorded AI claim B

is it still in business

critical

currently operating vendor

shut down in late 2024

purity level

low

98-99%

98.6%+

Both columns quote AI answers, not verified company facts. Resolve the entity, date and source before deciding whether a correction is warranted; different dates can explain an apparent conflict.

Question observed in the research

Benchmark answers to this question

Company mentions

Company recommendations

What company makes the best peptides?

4

1

1

What is the #1 peptide company?

3

1

1

These are recorded answer observations, not search volume, verified demand, or proof of missing website content.

Selected owned-page review candidate: https://blueskypeptide.com/about-us.

Selected third-party review candidate: https://realpeptides.co/blue-sky-peptide-legit-review-2026-safety-analysis/.

Blue Sky Peptide shows the widest gap in the set between appearances and affirmative recommendations, with neutral and negative framing outweighing positive. That pattern is a recorded description of answer wording, not an explanation of why it occurs.

The recorded conflicts about operating status and purity are numerous and several are rated critical. Proposed work is a careful fact check against current primary sources before any correction request, with the company kept out of the correction queue until its identity and status are confirmed.

Phoenix Pharmaceuticals

Questions This Section Answers

  • What measured visibility pattern and review priority does Phoenix Pharmaceuticals have in Peptide Suppliers?

Phoenix Pharmaceuticals recorded 178 mentions (39.29%) and 117 recommendations (25.83%) across 453 answers included in the benchmark. Top 3 placements numbered 94; first-place recommendations numbered 58. Framing among its mentions was 133 positive, 45 neutral and 0 negative.

This edition establishes a broader research baseline. Earlier editions used a narrower set of questions, so their figures are not treated as a performance trend.

AI answers contained 9 conflicting claims about Phoenix Pharmaceuticals: 0 critical, 4 high, 1 medium, 4 low. Of these, 4 were rated critical or high priority; the critical claims are included in that total. These ratings help prioritize fact-checking. They do not establish that a company or publisher made an error.

Review topic

Severity

Recorded AI claim A

Recorded AI claim B

operational status / availability

high

actively operating and recommended as a top institutional supplier

shut down operations

who can buy (customer eligibility)

high

Institutions/pharma only, not individual buyers

Listed as a research peptide vendor option for buyers seeking peptides online

Both columns quote AI answers, not verified company facts. Resolve the entity, date and source before deciding whether a correction is warranted; different dates can explain an apparent conflict.

Question observed in the research

Benchmark answers to this question

Company mentions

Company recommendations

What is the best peptide company to buy from in the USA?

3

3

3

Where can I buy peptides wholesale?

4

3

3

These are recorded answer observations, not search volume, verified demand, or proof of missing website content.

Selected owned-page review candidate: https://phoenixpeptide.com/.

Selected third-party review candidate: https://onetwenty.com/blog/peptide-companies.

Phoenix Pharmaceuticals leads the peer set on presence, recommendations and placement, with no negative framing recorded. Its position is the strongest in the benchmark, and the work here is about protecting accuracy rather than building reach.

The recorded conflicts concern operating status and who can buy, both rated high priority. Proposed work is a fact check against current primary sources, followed by a page brief only where verified facts support the description answers give.

/ Take the next step

Want to Understand Your AI Citation Footprint?

We start every engagement with a full audit of how AI systems reference your brand today.

Measurable, Repeatable Programme

Build a durable foundation of credible citations that compounds over time and continues to influence AI answers as new queries emerge

Citation Architecture Review

Identify which high-authority community sources are and aren't working in your favour across AI platforms.

AI Visibility Audit

Understand exactly how LLMs are referencing your brand today and which sources are shaping those answers.

The CiteWorks five-step improvement plan

Step 1. Establish the baseline

Questions This Section Answers

  • What should the agency deliver when it works to establish the baseline for Peptide Suppliers?

Build a cohort scorecard that records mentions, recommendations and placement separately for each company, with the source answer and date attached to every entry. The scorecard should also note the screening scope used this month so future editions can be compared on the same basis. Each record needs an owner and a review status before any downstream work begins.

Step 2. Verify disputed facts

Questions This Section Answers

  • What should the agency deliver when it works to verify disputed facts for Peptide Suppliers?

AI answers contained 40 conflicting claims across 4 companies. Another 0 possible conflicts were excluded because their company matches were uncertain. The conflicting claims need fact-checking before any corrections are proposed.

Work through the recorded conflicts company by company, starting with those rated critical or high. For each, identify the entity, the date and the underlying source, then check current primary evidence before deciding whether a correction is warranted. Ambiguous company matches stay outside the queue, and a resolved conflict may simply be a difference in dates.

Step 3. Review owned pages

Questions This Section Answers

  • What should the agency deliver when it works to review owned pages for Peptide Suppliers?

Assign page briefs to the supplied owned-page candidates, but only after the facts on each page have been verified against current primary sources. A brief should state what the page needs to establish, not assume what it currently says. Pages tied to unresolved conflicts wait until the fact check concludes.

Step 4. Review third-party sources

Questions This Section Answers

  • What should the agency deliver when it works to review third-party sources for Peptide Suppliers?

Prepare source-review packages for the third-party pages that matter most to each company, checking current contents before any request is drafted. A citation in an answer does not show that the page influenced it, so requests should rest on verified inaccuracies rather than on citation counts alone.

Step 5. Address buyer questions and measure again

Questions This Section Answers

  • What should the agency deliver when it works to address buyer questions and measure again for Peptide Suppliers?

Turn the observed buyer questions into content briefs that answer them directly, using verified company facts. Track delivered work separately from answer outcomes, and measure again on the same screening scope so the next edition can be compared with this baseline without claiming causation.

Third-party authority and citation opportunities

Questions This Section Answers

  • Which cited publisher pages support targeted source review in Peptide Suppliers?

Publisher page selected for review

Citation appearances in all captured answers

Companies covered by the page selection

https://onetwenty.com/blog/peptide-companies

77

AminoVault, Phoenix Pharmaceuticals

https://biosynth.com/peptides

51

Peptides Source, Biotech Peptides

https://phoenixpeptide.com/

91

AminoVault

https://phoenixpeptide.com/product_category/peptides/

64

Peptides Source

https://americanpeptides.us/

55

Biotech Peptides

https://linkedin.com/pulse/9-peptide-companies-worth-trusting-after-2026-shakeout-dinesh-sahu-uh47c

43

Phoenix Pharmaceuticals

https://peptidestack.io/blog/core-peptides-review-2026

17

Core Peptides

https://peptideresearchreviews.com/articles/core-peptides-vs-roehn-2026

9

Core Peptides

https://realpeptides.co/blue-sky-peptide-legit-review-2026-safety-analysis/

8

Blue Sky Peptide

https://knowyourpeptide.com/vendors/blue-sky-peptide

4

Blue Sky Peptide

These pages are candidates for review, not confirmed errors. Citation appearances are counted across the captured answers and are not added again for each company.

The publisher list should be prioritized by relevance to a specific company and by whether the page's current contents can be verified, not by citation counts alone. A page cited often across answers is worth reading first, but citation frequency does not establish that the page shaped any answer.

Several candidates are company-owned pages, which makes them useful for confirming facts but not independent authorities. Third-party review and directory pages deserve earlier attention where they carry disputed claims. Proposed work is a read-and-verify pass on each selected page, followed by a request only where a verified inaccuracy exists.

What we'd prioritize first

Period

Deliverable

Completion criterion

Days 1–30

Baseline scorecard, scoped fact-review register and page/source shortlist

Each record has an owner, evidence requirement and review status

Days 31–60

Approved page briefs and justified publisher requests

Separate confirmed edits, no-change decisions, requests and responses

Days 61–90

Buyer-content briefs and a fresh scorecard

Record work completed separately from measured answer outcomes and comparability limits

Start with the fact dependencies, because several companies cannot be briefed or corrected until their operating status is confirmed. The recorded conflicts around Peptide Tech, Blue Sky Peptide, Core Peptides and Phoenix Pharmaceuticals should be resolved against current primary sources first, with ambiguous matches left out.

In parallel, build the baseline scorecard so this month's figures become a fixed reference. Page and publisher work follows verification, and buyer-question content comes last, once the facts it depends on are settled.

Methodology and conclusion

Questions This Section Answers

  • What do the Peptide Suppliers sample and source-review limits allow us to conclude?

This edition includes all relevant captured answers, including buyer questions reserved from the limited email report. Every captured answer was screened and every relevant answer was included in the figures. Mentions require the company to be identified in the answer; incidental uses of its name as an ordinary word are not counted. Mentions require the company to be identified in the answer; incidental uses of its name as an ordinary word are not counted. Ahrefs queries return a bounded brand-query sample, not every AI answer available.

This report covers 2026-11. The exact dates when the original AI answers were collected have not been verified. The visibility rates use 453 answers that met the benchmark's inclusion rules. A company is recommended only when the answer both endorses it and uses positive wording. Top 3 and first-place counts are part of those recommendations, not extra recommendations.

An answer can mention or recommend several companies, so company counts cannot be added to find the number of distinct answers. The net sentiment score is positive minus negative mentions, divided by all company mentions; it describes answer wording, not customer satisfaction.

The wider citation analysis covers 554 captured answers and 3581 appearances of cited URLs. Citation appearances across all captured answers differ from the number of benchmark answers citing a page and the number that also recommend a company. The current contents of cited pages and disputed company claims still need independent verification.

Monthly sample coverage:

Reporting month

Answers included

AI services covered

Services

Nov 2026

453

6

ChatGPT, Copilot, Gemini, Google AI Mode, Google AI Overviews, Perplexity

Earlier editions (July 2026, August 2026, September 2026 and October 2026) used a narrower set of questions. This edition includes all captured answers screened as relevant and establishes a broader baseline. Earlier figures remain in the archive; they are not used to claim a change in performance.

Future editions using the same screening scope can be compared against this baseline.

This edition covers a single month and a broad screening scope, so the figures describe recorded answer behavior rather than a trend. Mentions, recommendations and placement are counted separately, and a company can appear in several answers, so counts should not be added to estimate distinct answers.

The proposed next steps are a fixed baseline scorecard, a scoped fact-check of the recorded conflicts, verified page and source reviews, and buyer-question content. Agency work can be logged alongside the scorecard so that activity and answer outcomes are read as separate records; future editions on the same scope can be compared with this baseline, with any movement described rather than credited to the work.

This analysis is based on the source benchmark: Peptide Suppliers AI visibility benchmark

/ Learn More

Understanding AI search visibility.

AI search experiences create answers by pulling information from many places online and summarizing it into a single response.

What Is AI Citation Intelligence?
AI citation intelligence is the process of measuring where AI platforms source their information and how frequently a brand is mentioned or referenced in AI-generated responses. Because LLMs synthesize across multiple sources, the sites and brands that appear repeatedly tend to influence how a topic or company is framed. This practice focuses on identifying which sources shape AI outputs and tracking brand visibility across different AI systems.
What Is Citation Architecture?
Citation architecture describes the set of sources that consistently inform how AI systems talk about a brand, product, or topic. LLMs draw from websites, articles, forums, and public discussion, and the sources they rely on most often become the backbone of their answers. Building strong citation architecture means ensuring that accurate, credible, high authority sources are the ones most likely to shape the way AI tools summarize and recommend a brand.
What Is Generative Engine Optimization?
Generative engine optimization (GEO) is the practice of improving the chances that AI systems use and cite your brand or content when generating answers. While traditional SEO is centered on ranking pages in search results, GEO focuses on how LLMs retrieve, interpret, and combine information when responding to a question. The objective is to strengthen the content and sources AI systems rely on, so your brand is treated as a trusted reference in AI responses.
What Is AI Share of Voice?
AI share of voice tracks how often a brand appears in AI-generated answers compared with competitors in the same category. It reflects visibility across AI platforms such as ChatGPT, Gemini, Claude, and Perplexity. Monitoring AI share of voice helps organizations see whether AI systems consistently include and recommend their brand for key queries or whether competitor brands are showing up more often.

About The Author

Mark Huntley

Mark Huntley

Founder and CEO

Mark Huntley, J.D. is founder of CiteWorks Studio, a strategic advisory focused on visibility, authority, and recommendation presence in AI-shaped search environments. His work centers on embedding-level GEO, vector optimization, and cosine gap engineering — helping brands align their digital presence with the retrieval systems that increasingly shape discovery, interpretation, and choice.

Archived editions

Browse earlier published research snapshots for this article. The latest edition remains at the current URL.

VIEW ALL CASE STUDIESREQUEST AN AI VISIBILITY AUDIT